Pacific Biosciences of California, Inc. PACB
Set alert
At close · Oct 30
After hours · Oct 30, 7:34 PM ET
- YTD
- +39.30%
- 1 year
- +34.28%
- Open
- 2.75
- Prev close
- 2.90
- Mkt cap
- 809.71M
- Vol
- 13.74M
- Avg vol
- 11.85M
- EPS
- -0.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.41
- High
- 2.82
- Forward P/E
- -2.84
- Beta
- 2.01
- Short ratio
- 4.46
- Inst. own
- 84.53%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.01
- 200-d avg
- 2.02
- 1y target
- 3.02
6M chart
Signals (28)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 3 days ago |
| RSI: Overbought | Oct 28, 2026 | 3 days ago |
| MACD: Sell Signal | Oct 13, 2026 | 2 weeks ago |
| RSI: Overbought | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bullish | Jul 30, 2026 | 3 months ago |
| SMA: Bearish | Jul 17, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 24, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
| SMA: Bearish | May 8, 2026 | 5 months ago |
| MACD: Sell Signal | May 8, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
Key statistics
- Market cap
- 568.03M
- Enterprise value
- 989.12M
- Trailing P/E
- 0.00
- Forward P/E
- -2.84
- PEG ratio
- 0.00
- Price / sales
- 3.28
- Price / book
- 1.17
- EPS (TTM)
- -1.46
- Beta
- 2.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -227.69%
- Revenue (TTM)
- 173.15M
- Revenue growth
- -28.20%
- Free cash flow
- -190.76M
- Total cash
- 471.15M
- Total debt
- 920.75M
- Return on equity
- -64.80%
- Shares outstanding
- 294.32M
- Short % of float
- 21.05%
- 50-day average
- 2.01
- 200-day average
- 2.02
Analyst view
Consensus: buy
- Target (low)
- 2.00
- Target (mean)
- 3.02
- Target (high)
- 6.00
- Strong buy1
- Buy6
- Hold8
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.17551.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.20 | -0.17 | +0.03 | +15.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.24 | -0.20 | +0.04 | +16.67% |
| May 9, 2024 | Mar 1, 2024 | -0.26 | -0.26 | 0.00 | 0.00% |
| Feb 15, 2024 | Dec 1, 2023 | -0.31 | -0.27 | +0.04 | +12.90% |
| Oct 30, 2023 | Sep 1, 2023 | -0.30 | -0.27 | +0.03 | +10.00% |
| Aug 2, 2023 | Jun 1, 2023 | -0.34 | -0.26 | +0.08 | +23.53% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | UBS | down | Buy | Neutral |
| Nov 11, 2024 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Nov 11, 2024 | Piper Sandler | main | Neutral | Neutral |
| Aug 28, 2024 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Aug 13, 2024 | Stephens & Co. | main | Overweight | Overweight |
| Aug 12, 2024 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- pacb.com
News
- Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts
- 10 Health Care Stocks Whale Activity In Today’s Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday
- PacBio to Participate in Upcoming Investor Conferences
- Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
- PacBio And Verily Health Announce Multi-Year Strategic Collaboration To Integrate PacBio HiFi Sequencing With Verily Health’s Governed Data And AI Platform
- Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday
- PacBio, TychoBio Collaborate Over Generation Of RNA Data To Train Models For RNA Therapy Design
- Progress Software, Nft And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
Your note
Sign in to keep a note on PACB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| EIDEL JEFFREY | Officer | Sale | Aug 18, 2024 | 869,938 |
| ERICSON WILLIAM W | Director | Stock Award(Grant) | Jun 17, 2024 | 41,616 |
| HENRY CHRISTIAN O | Chief Executive Officer | Sale | Sep 15, 2024 | 2,497,760 |
| KIM SUSAN G | Chief Financial Officer | Sale | Sep 29, 2024 | 695,654 |
| LIVINGSTON RANDALL S | Director | Stock Award(Grant) | Jun 17, 2024 | 22,821 |
| MILLIGAN JOHN F | Director | Stock Award(Grant) | Jun 17, 2024 | 132,821 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK Investment Management, LLC | 12.20% | 33,406,401 | 64.47M | Sep 29, 2024 |
| Madrone Advisors, LLC | 8.54% | 23,391,915 | 45.15M | Sep 29, 2024 |
| Blackrock Inc. | 8.49% | 23,252,682 | 44.88M | Sep 29, 2024 |
| Edmond De Rothschild Holding S.A. | 7.42% | 20,307,880 | 39.19M | Sep 29, 2024 |
| Vanguard Group Inc | 6.44% | 17,642,804 | 34.05M | Sep 29, 2024 |
| Sumitomo Mitsui Trust Holdings, Inc. | 4.33% | 11,865,766 | 22.90M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Tr-ARK Innovation ETF | 6.91% | 18,937,397 | 36.55M | Oct 30, 2024 |
| ARK ETF Tr-ARK Genomic Revolution ETF | 4.52% | 12,389,944 | 23.91M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 3.26% | 8,930,679 | 17.24M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.57% | 7,047,500 | 13.60M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.45% | 3,984,497 | 7.69M | Sep 29, 2024 |
| Smallcap World Fund | 1.24% | 3,390,000 | 6.54M | Sep 29, 2024 |